Apretude, the first and only long-acting injectable PrEP option given as few as six times per year to reduce the risk of HIV acquisition.1

Apretude is administered as a single 600-mg (3-mL) intramuscular (IM) injection into the buttocks.1

*after the initiation period*

**ADMINISTRATION**

**INDICATION AND IMPORTANT SAFETY INFORMATION FOR APRETUDE (CABOTEGRAVIR EXTENDED-RELEASE INJECTABLE SUSPENSION) FOR HIV PREVENTION**

**APPLICATION**

Apretude is an integrase strand inhibitor (INSTI) cabotegravir extended-release injectable suspension. INSTIs, like cabotegravir, inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic disease.

Apretude is not approved for use anywhere outside of the U.S.

**CONTRAINDICATIONS**

- Individuals who are pregnant or are breastfeeding.
- Previous hypersensitivity reaction to cabotegravir.
- Unknown or positive HIV-1 status.

**WARNINGS AND PRECAUTIONS**

- Risk of developing resistance to Apretude if an individual acquires HIV-1 either before or while taking Apretude or following discontinuation of Apretude.
- Potential risk of developing resistance to Apretude if an individual acquires HIV-1 either before or while taking Apretude or following discontinuation of Apretude. Resistance risk of HIV-1 acquisition exceeds that of resistance risk to Apretude. Resistance risk of HIV-1 acquisition is unknown.
- Resistance concentrations of cabotegravir may remain in the systemic circulation of individuals up to 12 months or longer.
- Potential risk of developing resistance to Apretude if an individual acquires HIV-1 either before or while taking Apretude or following discontinuation of Apretude.
- Drug-resistant HIV-1 variants have been identified with use of Apretude for HIV-1 infection. Drug-resistant HIV-1 variants may reduce the effectiveness of Apretude.

**ADVERSE REACTIONS**

The most common adverse reactions (all grades) observed in at least 1% of subjects receiving Apretude were injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea, dizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back pain, and upper respiratory tract infection.

**DRUG INTERACTIONS**

- Drugs that induce uridine diphosphate glucuronosyltransferase (UGT1A1) may significantly decrease plasma concentrations of cabotegravir.
- Refer to the full prescribing information for important drug interactions with Apretude.

**USE IN SPECIFIC POPULATIONS**

- Pediatric: Not recommended in individuals weighing less than 35 kg.
- Lactation: Assess the benefit-risk of using Apretude to the infant while breastfeeding due to the potential for adverse reactions and residual concentrations of cabotegravir in the systemic circulation for up to six months or longer after discontinuation.
- Pediatrics: Not recommended in individuals weighing less than 35 kg.

Please see full prescribing information included in the package insert.

**ABOUT APRETUDE INJECTIONS**

**INITIATION**

- Month 1
- Month 2

**CONTINUATION**

- Month 4
- Month 6
- Month 8
- Month 10

Apretude injections are given every two months after.

大约每两个月给药一次。